BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27093553)

  • 1. Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.
    Ren J; Chen GG; Liu Y; Su X; Hu B; Leung BC; Wang Y; Ho RL; Yang S; Lu G; Lee CG; Lai PB
    PLoS One; 2016; 11(4):e0153863. PubMed ID: 27093553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
    Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
    Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
    Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17β-Estradiol inhibits testosterone-induced cell proliferation in HepG2 by modulating the relative ratios of 3 estrogen receptor isoforms to the androgen receptor.
    Xu Z; Liu J; Jianxin C; Yongliang Z; Pan X
    J Cell Biochem; 2018 Nov; 119(10):8659-8671. PubMed ID: 30058741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
    Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
    Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib.
    Zhang Y; Feng J; Mi Y; Fan W; Qin R; Mei Y; Jin G; Mao J; Zhang H
    Drug Metab Dispos; 2024 May; 52(6):555-564. PubMed ID: 38565301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
    Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
    Tang W; Xue R; Weng S; Wu J; Fang Y; Wang Y; Ji L; Hu T; Liu T; Huang X; Chen S; Shen X; Zhang S; Dong L
    Int J Cancer; 2015 Mar; 136(6):E475-87. PubMed ID: 25196217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta.
    LaVallee TM; Zhan XH; Herbstritt CJ; Kough EC; Green SJ; Pribluda VS
    Cancer Res; 2002 Jul; 62(13):3691-7. PubMed ID: 12097276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
    Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
    Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta.
    Bhavnani BR; Tam SP; Lu X
    Endocrinology; 2008 Oct; 149(10):4857-70. PubMed ID: 18599548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
    Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
    Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
    Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
    Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
    Yu W; Gu K; Yu Z; Yuan D; He M; Ma N; Lai S; Zhao J; Ren Z; Zhang X; Shao C; Jiang GL
    Cancer Lett; 2013 Feb; 329(1):109-17. PubMed ID: 23142289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
    Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.